INTRODUCTION
Chronic graft-versus-host disease (cGVHD) remains the leading cause for late morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Although half of the patients respond to first-line treatment, prognosis of steroid refractory cGVHD remains poor [1] [2] [3] . Primary treatment of cGVHD is based on controlled trials and consists of prednisone given with or without a calcineurin inhibitor (CNI). In contrast, evidence in steroid refractory cGVHD is limited almost
